Who qualifies for a GLP-1 for weight loss
Adults may be eligible for a GLP-1 weight-loss drug when their BMI is 30 or more, or 27 or more with at least one weight-related health condition. That is the group the main trials behind Wegovy and Zepbound enrolled. The labels themselves say obesity, or overweight with a weight-related condition, and print no BMI number. A clinician makes the final call after an online or in-person visit.
What the FDA labels say
The Wegovy label (revised June 2026) covers weight loss "in adults and pediatric patients aged 12 years and older with obesity" and "adults with overweight in the presence of at least one weight-related comorbid condition." The Zepbound label (revised August 2026) uses the same words for adults, and Zepbound is also approved "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."
Wegovy has two more uses on its label: lowering the risk of heart attack, stroke and heart death in adults with heart disease and obesity or overweight, and a liver disease called MASH with moderate to advanced scarring.
What the BMI numbers mean
| Your BMI | CDC category | Usual GLP-1 starting rule |
|---|---|---|
| 30 or more | Obesity | May be eligible on BMI alone |
| 27 to 29.9 | Overweight | May be eligible with at least one weight-related condition |
| 25 to 26.9 | Overweight | Usually not: the main trials started at 27 |
| Under 25 | Healthy weight or underweight | Not for weight loss |
The labels do not print a BMI number. The CDC calls a BMI of 30 or more obesity and 25 to under 30 overweight. The trials that led to approval, STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, enrolled adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition. That is why a BMI of 25 or 26 counts as overweight but is usually not enough for a weight-loss prescription.
Which health conditions count
Weight-related conditions that clinicians look at include high blood pressure, high cholesterol or other blood fat problems, prediabetes or type 2 diabetes, obstructive sleep apnea and heart disease (STEP 1 and SURMOUNT-1 left out people with diabetes; separate trials studied them). You list them in the online intake, and the quiz above lets you tick them.
What can rule a GLP-1 out
- A personal or family history of medullary thyroid cancer (MTC), or MEN 2. Both labels list these as contraindications.
- A serious allergic reaction to semaglutide or tirzepatide before. Also a contraindication on both labels.
- Pregnancy. The Zepbound label says weight loss "may cause fetal harm" and to stop the drug when a pregnancy is recognized; the Wegovy label says to stop at least 2 months before a planned pregnancy.
Tell the clinician about any history of pancreatitis, gallbladder disease, kidney problems or diabetic eye disease too. If you use birth control pills, the Zepbound label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. The online visit checks your health history before anything is prescribed.
What online programs ask
Online programs ask for your height, weight, health conditions, current medicines and, at some programs, a photo ID or recent labs. A licensed clinician reviews the answers and decides. You can compare the programs that do this visit in the list above.
Medicare and insurance
Eligibility for the drug and coverage for the drug are separate questions. If you are on Medicare, see does Medicare cover Wegovy for the current rules. The programs above sell self-pay plans, so you do not need insurance to use them.
Sources: Wegovy prescribing information (revised 6/2026), Zepbound prescribing information (revised 8/2026), CDC adult BMI categories, STEP 1, NEJM 2021, SURMOUNT-1, NEJM 2022. Read Nov 6, 2026.





